MA52186A - Glycoformes afucosylées totales d'anticorps produits en culture cellulaire - Google Patents

Glycoformes afucosylées totales d'anticorps produits en culture cellulaire

Info

Publication number
MA52186A
MA52186A MA052186A MA52186A MA52186A MA 52186 A MA52186 A MA 52186A MA 052186 A MA052186 A MA 052186A MA 52186 A MA52186 A MA 52186A MA 52186 A MA52186 A MA 52186A
Authority
MA
Morocco
Prior art keywords
cell culture
antibodies produced
afucosylated glycoforms
total afucosylated
glycoforms
Prior art date
Application number
MA052186A
Other languages
English (en)
Inventor
Prince Bhebe
Matthew Jerums
Kurt Kunas
Irene Liu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA52186A publication Critical patent/MA52186A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA052186A 2018-03-26 2019-03-26 Glycoformes afucosylées totales d'anticorps produits en culture cellulaire MA52186A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862648308P 2018-03-26 2018-03-26

Publications (1)

Publication Number Publication Date
MA52186A true MA52186A (fr) 2021-02-17

Family

ID=66102281

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052186A MA52186A (fr) 2018-03-26 2019-03-26 Glycoformes afucosylées totales d'anticorps produits en culture cellulaire

Country Status (15)

Country Link
US (1) US20210079065A1 (fr)
EP (1) EP3775251A1 (fr)
JP (2) JP2021519068A (fr)
KR (1) KR20200135781A (fr)
CN (1) CN111954719A (fr)
AU (1) AU2019243848A1 (fr)
BR (1) BR112020019559A2 (fr)
CA (1) CA3093853A1 (fr)
CL (1) CL2020002450A1 (fr)
EA (1) EA202092286A1 (fr)
IL (2) IL313983A (fr)
MA (1) MA52186A (fr)
MX (1) MX2020009907A (fr)
SG (1) SG11202009216YA (fr)
WO (1) WO2019191150A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CA3152547A1 (fr) 2019-09-26 2021-04-01 Amgen Inc. Procedes de production de compositions d'anticorps
KR20220115998A (ko) * 2019-12-19 2022-08-19 메르크 파텐트 게엠베하 단백질의 글리코실화 프로파일을 조절하기 위한 방법 및 조성물
EP4229080A1 (fr) 2020-10-15 2023-08-23 Amgen Inc. Glycanes relatifs non appariés dans des procédés de production d'anticorps
US20240279704A1 (en) 2021-06-07 2024-08-22 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113960232B (zh) * 2021-10-28 2024-02-20 苏州大学 一种基于唾液特异性岩藻糖基化结构糖谱及其检测方法和应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5714465A (en) 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US6630143B1 (en) 1993-05-24 2003-10-07 Immunex Corporation Antibodies against flt3 ligand
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
US6211150B1 (en) 1996-07-19 2001-04-03 Amgen Inc. Analogs of cationic proteins
JP2002509431A (ja) 1996-12-23 2002-03-26 イミュネックス・コーポレーション ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
CZ302262B6 (cs) 1997-04-16 2011-01-19 Amgen Inc. Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999031241A1 (fr) 1997-12-17 1999-06-24 Immunex Corporation Glycoproteines de surface cellulaire associees aux lymphomes b humains-ulbp, adn et polypeptides
JP2001526892A (ja) 1997-12-23 2001-12-25 イミュネックス・コーポレーション Ｓｉｇｉｒｒｄｎａおよびポリペプチド
EP1043335A4 (fr) 1997-12-25 2005-08-31 Japan Tobacco Inc Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
DE69926480T2 (de) 1998-01-23 2006-04-13 Immunex Corp., Thousand Oaks Acpl dna und polypeptide
CA2337712A1 (fr) 1998-08-07 2000-02-17 Immunex Corporation Molecules designees b7l-1
CA2337100C (fr) 1998-08-07 2011-09-20 Immunex Corporation Polypeptides des molecules d'adhesion des cellules dendritiques lymphoides (ldcam) et polynucleotides codant lesdits polypeptides
JP4454859B2 (ja) 1998-11-13 2010-04-21 イミュネックス・コーポレーション ヒトｔｓｌｐｄｎａおよびポリペプチド
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
EP2292665B1 (fr) 2000-05-26 2015-07-08 Immunex Corporation Utilisation des anticorps de l'interleukine-4 et compositions correspondantes
ES2327102T3 (es) 2000-09-05 2009-10-26 Amgen Inc. Moleculas analogas al receptor de tnf y usos de las mismas.
PE20020801A1 (es) 2001-01-05 2002-09-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
WO2003024389A2 (fr) 2001-07-30 2003-03-27 Immunex Corporation Imx97018, polypeptide humain de type ataxine-1
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP1448588A4 (fr) 2001-10-23 2006-10-25 Psma Dev Company L L C Anticorps et multimeres de proteines psma
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2003048327A2 (fr) 2001-12-03 2003-06-12 Abgenix, Inc. Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2002361887A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Use of antibodies against the muc18 antigen
EP1467756A4 (fr) 2001-12-28 2007-03-21 Abgenix Inc Procedes d'utilisation d'anticorps anti-muc18
DE60220719T2 (de) 2001-12-28 2008-03-06 Amgen Fremont Inc. Antikörper gegen das muc18-antigen
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
SI1527100T1 (sl) 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
MEP18108A (en) 2002-08-19 2010-06-10 Astrazeneca Ab Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
AU2004260936B2 (en) 2003-06-27 2010-06-10 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
SI1648509T1 (sl) 2003-07-15 2012-12-31 Amgen Inc. Humana protitelesa, ki nevtralizirajo anti-ngf, kot selektivni inhibitorji poti nfg
AU2004261941B2 (en) 2003-07-25 2008-04-10 Amgen Inc. Antagonists and agonists of LDCAM and methods of use
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ATE548388T1 (de) 2003-11-07 2012-03-15 Immunex Corp An den interleukin-4-rezeptor bindende antikörper
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
EP1751191A2 (fr) 2004-04-23 2007-02-14 Amgen Inc. Anticorps de l'angiogenèse inhibant des domaines de cd148
AU2005249381A1 (en) 2004-04-23 2005-12-15 Amgen Inc. Antibodies of angiogenesis inhibiting domains of CD148
CA2574881C (fr) 2004-08-04 2013-01-08 Amgen Inc. Anticorps contre dkk-1
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
MX2007005866A (es) 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
CA2589860A1 (fr) 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
WO2006081139A2 (fr) 2005-01-26 2006-08-03 Abgenix, Inc. Anticorps diriges contre interleukine-1 beta
US8323645B2 (en) 2005-03-24 2012-12-04 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
EA201100642A1 (ru) 2005-04-25 2011-12-30 Пфайзер Инк. Антитела к миостатину
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CN101321783B (zh) 2005-07-18 2015-08-26 安姆根有限公司 人抗-b7rp1中和抗体
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
PL2447283T3 (pl) 2005-09-07 2015-12-31 Amgen Fremont Inc Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 (ALK-1)
ES2385054T3 (es) 2005-12-13 2012-07-17 Medimmune Limited Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
JP2009537143A (ja) 2006-05-19 2009-10-29 アムゲン インコーポレイティッド Ｓａｒｓコロナウイルスに対する抗体
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CA2682927A1 (fr) 2007-04-02 2008-10-16 Amgen Fremont Inc. Anticorps anti-ige
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
SI2188313T1 (en) 2007-08-21 2018-04-30 Amgen, Inc. HUMAN C-FMS ANTIGEN TRANSFER PROTEIN
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2261254A3 (fr) 2007-12-21 2011-04-13 Amgen, Inc Anticorps anti-amyloïdes et leurs utilisations
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
SG10201801337WA (en) 2009-03-20 2018-03-28 Amgen Inc Alpha-4-Beta-7 Heterodimer Specific Antagonist Antibody
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CN103320388B (zh) * 2012-03-20 2015-10-28 无锡药明康德生物技术股份有限公司 提高抗体表达量和改良糖基化水平的细胞培养方法
KR102062784B1 (ko) * 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
MX369395B (es) * 2014-02-27 2019-11-07 Hoffmann La Roche Modulacion del crecimiento celular y glucosilacion en la produccion de glucoproteina recombinante.
CA2969225C (fr) * 2014-12-01 2023-08-22 Amgen Inc. Procede de manipulation du taux de contenu de glycane d'une glycoproteine
EP3925970A1 (fr) * 2015-11-02 2021-12-22 F. Hoffmann-La Roche AG Procédés de fabrication de formes fucosylées et afucosylées d'une protéine
CN108350476A (zh) * 2015-11-11 2018-07-31 阿雷斯贸易股份有限公司 调节重组蛋白生产状况的方法
MX2018008448A (es) * 2016-01-06 2019-05-30 Oncobiologics Inc Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.
US20190161543A1 (en) * 2016-01-06 2019-05-30 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
WO2017134667A1 (fr) * 2016-02-02 2017-08-10 Insight Biopharmaceuticals Ltd. Procédés de génération d'anticorps

Also Published As

Publication number Publication date
JP2024019717A (ja) 2024-02-09
AU2019243848A1 (en) 2020-09-17
CN111954719A (zh) 2020-11-17
MX2020009907A (es) 2020-10-14
SG11202009216YA (en) 2020-10-29
CA3093853A1 (fr) 2019-10-03
CL2020002450A1 (es) 2020-12-28
IL276910B1 (en) 2024-08-01
EP3775251A1 (fr) 2021-02-17
EA202092286A1 (ru) 2021-03-18
WO2019191150A1 (fr) 2019-10-03
JP2021519068A (ja) 2021-08-10
KR20200135781A (ko) 2020-12-03
BR112020019559A2 (pt) 2021-01-12
IL313983A (en) 2024-08-01
IL276910A (en) 2020-10-29
US20210079065A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
MA52186A (fr) Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
MA47775A (fr) Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA46290A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
WO2015176066A3 (fr) Protéine associée à lpa et expression d'arn
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
BR112012020958A2 (pt) "meio de cultura para a criação e/ou diferenciação de células da linhagem hemapo
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA54139A (fr) Formulation d'anticorps
SG11202009389QA (en) Use of nw_003613638.1 in cho cell genome for stable expression of protein
EP4076526A4 (fr) Nouveaux anticorps ddr1 et leurs utilisations
MA55362A (fr) Formulations stabilisées contenant des anticorps anti-il-33
SG11202010741WA (en) Use of nw_006882456.1 in cho cell genome for stable expression of proteins
IL288819A (en) Methods for cell culture and preparations for antibody production
MA45831A (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation
MA47106A (fr) Formulations d'anticorps anti-tnf alpha
MA53557A (fr) Procédés de culture cellulaire continue
ZA202203272B (en) Anti-stem cell factor antibodies and methods of use thereof
MA46469A (fr) Minicellules bactériennes pour l'administration d'adjuvants d'acides nucléiques et leurs procédés d'utilisation
EP3192564A8 (fr) Composition de protection orale
MA55761A (fr) Formulations et anticorps anti-cd38